Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Washington University School of Medicine, St. Louis, MO, USA; Circulogix Inc., St. Louis, MO, USA.
Cell Rep Med. 2023 Oct 17;4(10):101196. doi: 10.1016/j.xcrm.2023.101196. Epub 2023 Sep 18.
Liquid biopsy, through isolation and analysis of disease-specific analytes, has evolved as a promising tool for safe and minimally invasive diagnosis and monitoring of tumors. It also has tremendous utility as a companion diagnostic allowing detection of biomarkers in a range of cancers (lung, breast, colon, ovarian, brain). However, clinical implementation and validation remains a challenge. Among other stages of development, preanalytical variables are critical in influencing the downstream cellular and molecular analysis of different analytes. Although considerable progress has been made to address these challenges, a comprehensive assessment of the impact on diagnostic parameters and consensus on standardized and optimized protocols is still lacking. Here, we summarize and critically evaluate key variables in the preanalytical stage, including study population selection, choice of biofluid, sample handling and collection, processing, and storage. There is an unmet need to develop and implement comprehensive preanalytical guidelines on the optimal practices and methodologies.
液体活检通过分离和分析疾病特异性分析物,已经发展成为一种安全、微创的肿瘤诊断和监测的有前途的工具。它也具有巨大的应用价值,作为一种伴随诊断,可以检测多种癌症(肺癌、乳腺癌、结肠癌、卵巢癌、脑癌)中的生物标志物。然而,临床实施和验证仍然是一个挑战。在其他开发阶段,分析前变量对于影响不同分析物的下游细胞和分子分析至关重要。尽管已经取得了相当大的进展来解决这些挑战,但仍然缺乏对诊断参数的全面评估以及关于标准化和优化方案的共识。在这里,我们总结并批判性地评估了分析前阶段的关键变量,包括研究人群的选择、生物流体的选择、样本的处理和收集、处理和储存。需要制定和实施关于最佳实践和方法的综合分析前指南。